Bone Biologics (BBLG) Stock Statistics & Valuation Metrics
Total Valuation
Bone Biologics has a market cap or net worth of $1.29M. The enterprise value is -$1.89T.
- Market Cap
- $1.29M
- Enterprise Value
- -$1.89T
Share Statistics
Bone Biologics has 3,389,057 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,389,057
- Owned by Insiders
- 0.02%
- Owned by Institutions
- 0.95%
Financial Efficiency
Bone Biologics’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -60.16%.
- Return on Equity (ROE)
- -0.58
- Return on Assets (ROA)
- -0.54
- Return on Invested Capital (ROIC)
- -60.16%
- Return on Capital Employed (ROCE)
- -0.60
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.55M
- Employee Count
- 2
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Bone Biologics is -0.22. Bone Biologics’s PEG ratio is -0.01.
- PE Ratio
- -0.22
- PS Ratio
- 0.00
- PB Ratio
- 0.23
- Price to FCF
- -0.49
- Price to Operating Cash Flow
- -0.54
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Bone Biologics had revenue of 0 and earned -3.11M in profits. Earnings per share was -2.65.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -3.23M
- Pretax Income
- -3.11M
- Net Income
- -3.11M
- EBITDA
- -3.11M
- Earnings Per Share (EPS)
- -2.65
Cash Flow
In the last 12 months, operating cash flow was -2.57M and capital expenditures 0, giving a free cash flow of -2.57M billion.
- Operating Cash Flow
- -2.57M
- Free Cash Flow
- -2.57M
- Free Cash Flow per Share
- -0.69
Dividends & Yields
Bone Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -206.55%
- Earnings Yield
- -207.15%
Stock Price Statistics
- Beta
- 1.17
- 52-Week Price Change
- -82.63%
- 50-Day Moving Average
- 0.49
- 200-Day Moving Average
- 1.05
- Relative Strength Index (RSI)
- 29.22
- Average Volume (3m)
- 379.60K
Financial Position
Bone Biologics as a current ratio of 13.85, with Debt / Equity ratio of 0.00%
- Current Ratio
- 13.85
- Quick Ratio
- 13.85
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.72
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Bone Biologics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Bone Biologics EV to EBITDA ratio is 1.68, with an EV/FCF ratio of 1.88.
- EV to Sales
- 0.00
- EV to EBITDA
- 1.68
- EV to Free Cash Flow
- 1.88
- EV to Operating Cash Flow
- 1.88
Balance Sheet
Bone Biologics has $6.09M in cash and marketable securities with $0.00 in debt, giving a net cash position of $6.09M billion.
- Cash & Marketable Securities
- $6.09M
- Total Debt
- $0.00
- Net Cash
- $6.09M
- Net Cash Per Share
- $1.80
- Tangible Book Value Per Share
- $1.59
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Bone Biologics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 92.16%
